LSZ-102

DB15362InvestigationalSmall molecule

LSZ-102 is under investigation in clinical trial NCT02734615 (Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers).

Mechanism: Pharmacologically active on Estrogen receptor
Curator reviewed
Formula / weight: C₂₅H₁₇F₃O₄S · 470.46 g/mol (avg)
Code names: LSZ-102

Resolves to

Compound

UNII0Y175XGX4PCAS2135600-76-7ChEMBLCHEMBL4076124

Structure

InChIKeySJXNPGGVGZXKKI-NYYWCZLTSA-NSMILESCC(F)(F)C1=C(C=CC(F)=C1)C1=C(OC2=CC=C(\C=C\C(O)=O)C=C2)C2=CC=C(O)C=C2S1

Targets

P03372ESR1

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with LSZ-102, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account